Patents by Inventor Jean Pierre Kinet

Jean Pierre Kinet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10238649
    Abstract: A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 26, 2019
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Publication number: 20180311236
    Abstract: Disclosed is a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein the patients are treated with a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a compound selected from imatinib, cromolyn sodium, midostaurin, BLU-285, bosutinib, ibrutinib, LAS189386, DP-2618, fostamatinib, dasatinib, sunitinib, axitinib, pazopanib, and toceranib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 1, 2018
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Patent number: 10092564
    Abstract: Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 9, 2018
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet, Colin Mansfield
  • Patent number: 10045978
    Abstract: The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 14, 2018
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Publication number: 20180117037
    Abstract: Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: March 24, 2017
    Publication date: May 3, 2018
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170340629
    Abstract: Disclosed is a method for treating breast cancer in a subject in need thereof, including administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a therapeutically effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: December 15, 2015
    Publication date: November 30, 2017
    Applicant: AB SCIENCE
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170196853
    Abstract: A treatment of patients afflicted with prostate cancer, wherein the treatment includes administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-Kit, PDGFR, LYN, FYN, or any combination thereof, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: June 2, 2014
    Publication date: July 13, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170119760
    Abstract: A mast cell inhibitor, a pharmaceutical composition and a method for treating patients afflicted with Progressive Supranuclear Palsy (PSP), wherein the patients are treated with a tyrosine kinase inhibitor, c-Kit inhibitor or mast cell inhibitor, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170020867
    Abstract: A method for treating patients afflicted with Crohn's disease, wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient for treatment of Crohn's disease.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 26, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20160263110
    Abstract: A treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS), wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient
    Type: Application
    Filed: November 4, 2014
    Publication date: September 15, 2016
    Inventors: Jean Pierre KINET, Alain MOUSSY, Colin MANSFIELD
  • Publication number: 20160244845
    Abstract: An in vitro method for determining the prognosis of pancreatic cancer in a patient includes the following steps: a) measuring the expression level of at least one gene chosen from the group consisting of: ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ and RPS23 or homologous genes, in a blood sample of the patient, b) predicting the outcome of the pancreatic cancer in the patient. a kit specifically designed to carry out such a method is also described.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Applicants: AB Science, ACOBIOM
    Inventors: David PIQUEMAL, Alain MOUSSY, Jean-Pierre KINET
  • Publication number: 20160175302
    Abstract: The present invention relates to a method for treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor, in combination with a therapeutically effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20160128999
    Abstract: A method for treating hepatic cancer in a subject in need thereof, which includes the administration to the subject a therapeutically effective amount of a tyrosine kinase inhibitor, in combination with a therapeutically effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: November 12, 2015
    Publication date: May 12, 2016
    Inventors: Alain MOUSSY, Jean-Pierre KINET
  • Publication number: 20160089368
    Abstract: The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.
    Type: Application
    Filed: December 2, 2015
    Publication date: March 31, 2016
    Inventors: Alain MOUSSY, Jean-Pierre KINET
  • Publication number: 20160022671
    Abstract: The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.
    Type: Application
    Filed: October 5, 2015
    Publication date: January 28, 2016
    Inventors: Alain MOUSSY, Jean-Pierre KINET
  • Publication number: 20150272945
    Abstract: A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity.
    Type: Application
    Filed: October 4, 2013
    Publication date: October 1, 2015
    Applicant: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet, David Piquemal
  • Patent number: 9078894
    Abstract: The present invention relates to the treatment of severe persistent asthma, and in particular severe persistent corticosteroid-dependent or corticosteroid-resistant asthma, comprising administration a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: July 14, 2015
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Patent number: 8906357
    Abstract: The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human multiple sclerosis.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: December 9, 2014
    Assignee: AB Science
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Publication number: 20140147415
    Abstract: The present invention relates to the treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), comprising administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof, in particular in an appropriate dosage regimen.
    Type: Application
    Filed: November 3, 2011
    Publication date: May 29, 2014
    Applicant: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Publication number: 20140051662
    Abstract: The present invention relates to the treatment of multiple myeloma, especially for the treatment of those patients with refractory or first relapsed multiple myeloma, and in particular patients with t(4;14) multiple myeloma, comprising administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof, administered in association with an additional care in multiple myeloma; for example, autologous stem-cell transplantation, targeted therapies, anti-myeloma agents such as alkylating agents, corticosteroids, or immunomodulatory agents, including bortezomib, lenalidomide, and dexamethasone.
    Type: Application
    Filed: April 4, 2012
    Publication date: February 20, 2014
    Applicant: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet